Clinical Trial Update: Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting pharmacokinetics and safety of Subgam-VF in primary immunodeficiency diseases, including CVID, X-linked agammaglobulinaemia, and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Common Variable Immunodeficiency
• Hyperimmunoglobulin Syndrome
• Immune Deficiency Disorders
• X-linked Agammaglobulinaemia

Drugs mentioned

• Subgam-VF

Snippet

Sponsor: Bio Products Laboratory | Conditions: Primary Immune Deficiency Disorders, Common Variable Immunodeficiency | Phase 3 | Status: COMPLETED | Results posted: 2018-09-12